Pfizer Inc on Monday announced that it would merge its off-patent drug business with generic drugmaker Mylan NV to create a global leader in low-cost treatment, a business that faces significant political pressure in the US.
The new entity, which is to be renamed upon the deal’s closure, would have a portfolio that includes impotence drug Viagra, cholesterol pills Lipitor, painkiller Lyrica and the life-saving EpiPen treatment for severe allergic reactions.
The merger comes amid rising competition in generic drugs from companies in India and elsewhere, a segment of pharma that is known for having low barriers to entry and commodity-like products.
Photo: AFP
Joining forces with Pfizer’s off-patent division, called Upjohn, would give Mylan access to more international markets.
The deal is also expected to result in US$1 billion in annual cost savings starting in 2023, the companies said.
“The combined organization will have a presence across nearly every continent and major market, establishing a new leadership position in Asia, and offering products capable of treating all major therapeutic areas,” said Mylan chairman Robert Coury, who is to serve as executive chairman of the new company.
This marks the latest move by Pfizer, which has grown into one of the world’s biggest pharma companies through a string of acquisitions.
The new company will be 57 percent owned by Pfizer shareholders and 43 percent owned by Mylan investors.
Upjohn president Michael Goettler is to serve as CEO of the new firm, while Mylan CEO Heather Bresch is to leave the company.
Pfizer, meanwhile, has announced deals in recent months to combine its consumer healthcare business with GlaxoSmithKline PLC’s unit, and to spend US$11.4 billion to acquire Array BioPharma Inc, which is known for drugs in development focused on oncology and rare disease.
Pfizer chief executive Albert Bourla said the deal with Mylan would sharpen the company’s focus on “breakthroughs that change patients’ lives.”
Separately, Pfizer reported that second-quarter profit jumped 30.3 percent to US$5 billion, due in part to a large one-time boosts from a favorable US tax settlement and a lower tax rate after the late 2017 US tax cut signed by US President Donald Trump.
Revenues dropped 1.5 percent to US$13.3 billion.
Pfizer also cut some of its financial forecasts for this year, citing the accounting of the GlaxoSmithKline and Array transactions.
Mylan’s share price surged 12.6 percent to end the day at US$20.78, while Pfizer fell 3.8 percent to US$41.45.
The US dollar was trading at NT$29.7 at 10am today on the Taipei Foreign Exchange, as the New Taiwan dollar gained NT$1.364 from the previous close last week. The NT dollar continued to rise today, after surging 3.07 percent on Friday. After opening at NT$30.91, the NT dollar gained more than NT$1 in just 15 minutes, briefly passing the NT$30 mark. Before the US Department of the Treasury's semi-annual currency report came out, expectations that the NT dollar would keep rising were already building. The NT dollar on Friday closed at NT$31.064, up by NT$0.953 — a 3.07 percent single-day gain. Today,
‘SHORT TERM’: The local currency would likely remain strong in the near term, driven by anticipated US trade pressure, capital inflows and expectations of a US Fed rate cut The US dollar is expected to fall below NT$30 in the near term, as traders anticipate increased pressure from Washington for Taiwan to allow the New Taiwan dollar to appreciate, Cathay United Bank (國泰世華銀行) chief economist Lin Chi-chao (林啟超) said. Following a sharp drop in the greenback against the NT dollar on Friday, Lin told the Central News Agency that the local currency is likely to remain strong in the short term, driven in part by market psychology surrounding anticipated US policy pressure. On Friday, the US dollar fell NT$0.953, or 3.07 percent, closing at NT$31.064 — its lowest level since Jan.
Hong Kong authorities ramped up sales of the local dollar as the greenback’s slide threatened the foreign-exchange peg. The Hong Kong Monetary Authority (HKMA) sold a record HK$60.5 billion (US$7.8 billion) of the city’s currency, according to an alert sent on its Bloomberg page yesterday in Asia, after it tested the upper end of its trading band. That added to the HK$56.1 billion of sales versus the greenback since Friday. The rapid intervention signals efforts from the city’s authorities to limit the local currency’s moves within its HK$7.75 to HK$7.85 per US dollar trading band. Heavy sales of the local dollar by
The Financial Supervisory Commission (FSC) yesterday met with some of the nation’s largest insurance companies as a skyrocketing New Taiwan dollar piles pressure on their hundreds of billions of dollars in US bond investments. The commission has asked some life insurance firms, among the biggest Asian holders of US debt, to discuss how the rapidly strengthening NT dollar has impacted their operations, people familiar with the matter said. The meeting took place as the NT dollar jumped as much as 5 percent yesterday, its biggest intraday gain in more than three decades. The local currency surged as exporters rushed to
RSS